Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Bert A. van der Reijden et al.|Blood|2018Cited by 1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet StudyDaniela Cilloni, David Grimwade, Aline Renneville et al.|Journal of Clinical Oncology|2009Cited by 434
Transcriptional diversity during lineage commitment of human blood progenitorsLu Chen, Asif U. Tamuri, Myrto Kostadima et al.|Science|2014Cited by 311
Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disordersJosé María Bastida, José Ramón González‐Porras, Marı́a Luisa Lozano et al.|Haematologica|2017Cited by 124